Posted by Michael Wonder on 18 May 2017
Health Canada approves Opdivo (nivolumab) for the treatment of squamous cell carcinoma of the head and neck
17 May 2017 - Latest approval of Opdivo marks the fourth indication for the immuno-oncology treatment offering hope for improved survival to more patients.
Health Canada has approved Opdivo (nivolumab) for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck in adults progressing on or after platinum-based therapy – the first and only immuno-oncology treatment in Canada for this indication.
